Addition of plerixafor to dasatinib does not improve survival or decrease disease burden of leukemic mice. Experiment was performed with both aggressive (A-E) and attenuated disease models (F-I). (A,F) Kaplan-Meier survival analysis of mice treated with dasatinib only or in combination with plerixafor (P = .2934, log-rank test). (B,G) FACS analysis for GFP⁺ cells to assess the proportion of leukemia cells in the peripheral blood. (C-D,H-I) Spleen and liver weight measured at necropsy of leukemic mice. (E) pCrkL levels measured by Western blot analysis in bone marrow cell lysates of dasatinib (Das) and dasatinib + plerixafor (Das + PLX) treated mice after indicated time of treatment compared with normal mice (NL) and untreated leukemic mice (UT).